Original news and analysis on international IP policy
Médicins Sans Frontières (MSF, Doctors without Borders) announced today that it has named a new executive director of its Access to Medicines Campaign, a high-impact advocacy initiative on international public health issues in Geneva and elsewhere. Today was the last day for current Executive Director Tido von Schoen-Angerer, who completed two three-year terms in the role.
The Group of Eight (G8) industrialised countries recently met to discuss major challenges to the global economy, climate change, food security and nutrition, and political and security issues. And the commitments they made on intellectual property rights reflect their current thinking on the issue.
The European Parliament has adopted a resolution on the patenting of essential biological processes.
With a generous pledge and a grand vision, Bill Gates launched the “Decade of Vaccines” two years ago. By endorsing a “Global Vaccine Action Plan” during the World Health Assembly, the world’s health authority stands as the lead agency in advancing the initiative.
One year since the adoption of the Pandemic Influenza Preparedness Framework, member states emphasised the importance of bio-sharing initiative and in some in cases raised concerns about the pace of implementation.
A full day and an evening of informal discussions was not enough for the World Intellectual Property Organization member states to reach agreement on the future work of the patent committee yesterday. Developed and developing countries held firm to their positions after reconvening in plenary past midnight, with disappointment as sole common ground.
World Health Organization member states have decided to establish a new mechanism for international collaboration to prevent and control “substandard, spurious, falsely-labelled, falsified and counterfeit medical products” (SSFFC). Excluding trade and intellectual property considerations, this mechanism is called to approach the problem strictly from a public health perspective.
A proposal at this week’s World Health Assembly to negotiate a binding convention on research and development for neglected diseases - those predominantly afflicting poor populations - ran into resistance from developed countries which hold the view that another approach might be possible. But an agreement was reached on a way forward for the expert report that recommended the binding convention.
The first global target on noncommunicable diseases has been gavelled through a World Health Assembly meeting. Member states have decided on a voluntary global target in reducing overall mortality from cardiovascular disease, cancer, diabetes or chronic respiratory disease.
The latest available documents of the closed-door meeting addressing recommendations on ways to finance neglected diseases largely afflicting developing countries show progress heading into this afternoon's session. They reflect efforts to agree on how to take the process forward, including agreement reached last night on putting the issue to regional groups later this year.
On the last day of the weeklong meeting of the WIPO committee on the law of patents, discussions are ongoing to find consensus on the future work of the committee. The week has been a theatre of strong stances dividing developed and developing countries on areas such as patents on health, patent flexibilities and the quality of patents.
A set of documents in use by today's closed-door negotiations on research and development for neglected diseases at the World Health Assembly lay out the core differences between WHO members. Negotiations are expected to last into the night as members try to agree on how to take forward recommendations from a key report - including to negotiate a binding convention on R&D for diseases left behind in the marketplace.